46 New Technology Helps Researchers Reinvent Buffer Screening


Avacta’s Optim protein stability analysis technology is helping researchers at Manchester University to approach buffer selection in an entirely new way. Dr Tom Jowitt, Manager of the University’s Biomolecular Analysis Core Facility, explained: “Academic institutions tend to work by word of mouth on protein projects, sticking to buffer conditions they are familiar with, or that have been used on previous projects within the laboratory. The buffers in use are often far from optimal for the protein of interest, but a lack of understanding of how to optimise buffer conditions means that these issues are rarely addressed.”


“As proteins become easier and easier to make in large quantities, we are trying to promote the concept of buffer screening, encouraging researchers to spend some time optimising buffer conditions at the start of each project, and this is where Avacta’s Optim instrument comes in. Due to the low sample volume required for each analysis, the Optim system makes it easy to screen a wide range of buffer conditions relatively quickly and cheaply. We can now screen 10 or 20 buffer conditions for a protein of interest in a short space of time, which simply wasn’t plausible


before we had the instrument, as the time and labour involved in performing multiple measurements using different technologies for each set of buffer conditions would have been prohibitive. This simple optimisation process can have quite a significant impact on protein stability and aggregation rates, particularly for difficult to handle proteins such as those within extracellular matrix. Thanks to the Optim system, the benefits of buffer screening are being widely recognised throughout the Department and, with approximately 250 research groups, the potential knock-on benefits could be highly significant.”


29370pr@reply-direct.com


Internationally Experienced Laboratory Manager Appointed to top Management Team


Effective 1 April, 2014, Michael Melingo will head marketing, sales and services of the Lab Products & Services Division at Sartorius. He will therefore succeed Dominique Baly, who will retire from the company as planned after reaching retirement age. Michael Melingo will report to CEO and Executive Board Chairman Dr Joachim Kreuzburg and be a member of the Group Executive Committee, the highest operational management level of the Sartorius Group.


Michael Melingo, who brings more than 30 years of experience in the industry as a sales and marketing executive, will be joining Sartorius from Metrohm, the Swiss manufacturer of analytical instruments, where he was CEO of its US subsidiary. Before that, he had worked for Baxter, Bio-Rad, Millipore and Waters in Europe and Asia. Michael Melingo is of Austrian nationality and a bioengineer who specialises in biochemistry and food technology.


“With Michael, we have found an exceptionally experienced manager to join our team, who has successfully managed international laboratory businesses. In his new role at Sartorius, he will focus on further developing the global sales, marketing and service organisation of our laboratory division business and strengthen its strategic positioning,” said Sartorius CEO and Executive Board Chairman Joachim Kreuzburg.


28776pr@reply-direct.com New Rotor Increases Centrifugation Throughput and Flexibility


Designed for applications that use common, disposable conical tubes, JA- 14.50 rotors from Beckman Coulter Life Sciences extend the applications and flexibility of the company’s Avanti centrifuge series, and can be used in Avanti J-26S, J-30I and J-E centrifuges. While greater capacity results in higher throughput, the rotors maintain the precision performance offered by products in the Avanti line and are the only high-performance rotors capable of spinning 50, 15, 5 and 1.5 mL conical tubes, and 50, 15 and 10 mL round bottom tubes and bottles at their maximum speeds.


Delivering a top speed of 14,000 rpm and rcf of 35,000 x g, JA-14.50 rotors hold up to 16 x 50 mL conical tubes and maximise the number of 50 mL conical tubes that can be processed in a single run. The fixed-angle rotor is intended for general pelleting of cells, bacteria and food products; separating proteins, viruses and subcellular fractions; running concentrators and columns; and for phase separation and binding studies.


Avanti centrifuges are available with a selection of BioCertified fixed-angle and swinging-bucket rotors, ranging in capacity from 360 mL to 6 L and all independently certified to contain liquids and aerosols. A BioCertified* dual- locking lid configuration, for workflows that include biohazardous samples, maintains biocontainment when removing the rotor from the centrifuge and transporting it to a containment hood. Rotors are also available in a standard single-locking lid configuration.


Avanti rotors, including the new JA-14.50 rotor, have a unique ID that is


tracked using magnetic sensors; the centrifugation system uses Dynamic Rotor Inertia Check and the ID for Automatic Rotor Identification and to ensure that no individual rotor exceeds the maximum speed permitted.


“We’re proud to introduce the JA-14.50 rotor – it improves workflows, saving scientists’ time, and is useful across a diverse array of applications where a variety of conical tube sizes are commonly used,” said Randall Lockner, Marketing Manager at Beckman Coulter Life Sciences. “Users can rely upon the quality, performance and efficiency for which Beckman Coulter centrifugation products are known.”


In addition to compatibility with current models, JA-14.50 rotors can be used in installed Avanti J-20 and J-25 centrifuges. 29348pr@reply-direct.com


The new VIAFLO II multichannel electronic pipette range from Integra combines ultra lightweight design and unsurpassed operation comfort enabling users to improve efficiency in their working environment.


VIAFLO II electronic pipettes together with Integra’s wide range of GripTip pipette tips form the perfect pipetting system. GripTips snap into place with minimal tip loading effort, providing a secure connection. GripTips never fall off and are always perfectly aligned, resulting in superior accuracy and precision results.


The integral colour screen together with the easy to navigate touch wheel user interface promote ease of set up and operation. All VIAFLO II pipettes offer a choice of up to 10 predefined pipetting modes (including repeat dispense, serial dilute and manual pipette) enabling users to quickly perform typical pipetting operations. For more demanding pipetting routines, up to 20 personalised custom programs can be created using the following steps: aspirate, dispense, mix, purge and prompt.


The ergonomic design of VIAFLO II electronic pipettes facilitates hours of tireless pipetting. With just one light press of the Run button a VIAFLO II electronic pipette can perform many procedures eliminating the time-consuming repetitive plunger motion required of manual pipettes.


Available in 8-, 12- and 16-channel versions, VIAFLO II electronic pipettes offer an optimised precision pipetting solution from 0.5 - 1250 microlitres.


For laboratories looking for further gains in productivity - VIAFLO II electronic pipettes are compatible with the Integra VIAFLO Assist enabling easy and affordable automation of these handheld devices.


29096pr@reply-direct.com


Troponin I (TnI) Point-of-Care Test Gains European Approval


Trinity Biotech is pleased to announce that its landmark, high sensitivity Meritas®


Troponin I (TnI) point-of-care (POC) test has


obtained CE marking, making it the only POC product capable of meeting all the guidelines stipulated by the world’s leading cardiac organisations for the detection of heart attacks. With CE marking achieved, the Company now intends to release the product for sale in Europe and other carefully selected markets through its specialist Cardiology Distributor network and direct selling teams.


Designed for use with the revolutionary, state-of-the-art Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI. Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top performing laboratory analysers, and are available in just 15 minutes. Turnaround times, patient care and outcomes are improved, helping to maximise the use of precious hospital resources and generate significant cost savings. Additional assays are currently being developed to extend the test menu further.


29071pr@reply-direct.com Lightweight Electronic Pipettes


INTERNATIONAL LABMATE - APRIL 2014


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84